Literature DB >> 2495219

Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease.

B O Olofsson1, G Dahlén, T K Nilsson.   

Abstract

We studied 234 consecutive patients who underwent coronary angiography because of severe angina pectoris. Tissue plasminogen activator (tPA), plasminogen activator inhibitor (PAI), and lipoprotein Lp(a) were measured in citrated plasma samples. The 214 patients showing significant coronary artery stenosis (greater than 50% reduction of luminal area in any of the great coronary arteries) had higher mean levels of tPA (P less than 0.001) and PAI (P less than 0.01) than a random population sample of similar age. PAI and tPA levels were higher in smokers than in either non-smokers or ex-smokers, and in patients with hypertension tPA was increased. Subjects with blood group A had a higher mean Lp(a) level than subjects with blood group O. There were positive correlations of PAI and tPA levels with serum triglycerides and with body mass index; Lp(a) correlated weakly with plasma fibrinogen concentrations. The findings suggest an impairment of the fibrinolytic system in patients with coronary artery disease, which offers a link between established risk factors and a plausible pathophysiological mechanism, namely thrombus turnover.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2495219     DOI: 10.1093/oxfordjournals.eurheartj.a059384

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  26 in total

1.  Small Molecule PAI-1 Functional Inhibitor Attenuates Vascular Smooth Muscle Cell Migration and Survival: Implications for the Therapy of Vascular Disease.

Authors:  Tessa M Simone; Paul J Higgins
Journal:  New Horiz Transl Med       Date:  2014-09-01

2.  Evaluation of overall fibrinolytic activity in patients with coronary artery ectasia: global fibrinolytic capacity.

Authors:  Abdullah Dogan; Bahattin Tunc; Oktay Ergene; Mehmet Ozaydin; Cem Nazli; Ahmet Altinbas; Omer Gedikli
Journal:  Int J Cardiovasc Imaging       Date:  2003-12       Impact factor: 2.357

3.  Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol.

Authors:  J H Jansson; B Johansson; K Boman; T K Nilsson
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 4.  Vessel wall-related risk factors in acute vascular events.

Authors:  L Badimon; J J Badimon; M Cohen; J H Chesebro; V Fuster
Journal:  Drugs       Date:  1991       Impact factor: 9.546

5.  Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study.

Authors:  Wolfgang Junge; Uwe Mellinger; Susanne Parke; Marco Serrani
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 6.  Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.

Authors:  Matteo Cesari; Marco Pahor; Raffaele Antonelli Incalzi
Journal:  Cardiovasc Ther       Date:  2010-07-07       Impact factor: 3.023

Review 7.  Cardiovascular pharmacology of hormone replacement therapy.

Authors:  G M Rosano; G Panina
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

8.  Plasma fibrinogen as cardiovascular risk factor.

Authors:  L Breimer
Journal:  Diabetologia       Date:  1995-05       Impact factor: 10.122

Review 9.  Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease.

Authors:  D de Bono
Journal:  Br Heart J       Date:  1994-06

10.  Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction.

Authors:  J H Jansson; K Boman; T K Nilsson
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.